Comments for the announcement (Announcement No. 48) are due November 15, 2026.[1]
For multinational pharmaceutical companies, the draft is not a general ban on in-licensing Chinese drug candidates. It distinguishes ownership of qualifying reusable platforms from rights to use them. Ownership-retaining licenses are expressly excluded from the two platform entries, but novel-target technology, pathogen technology, and interim registration require separate analyses.
Buyers should test whether the available rights and technical support permit global development, manufacturing transfers, and follow-on programs. A license may be legally available without providing the operational independence an acquisition was intended to secure.
Published industry data recorded 157 mainland Chinese innovative-drug and platform out-licenses in 2025, with $135.7 billion in potential value and $7 billion in upfront payments. The same source reported $99.7 billion for the first half of 2026.
Figures disclosed by the National Medical Products Administration on September 14 put 2026 out-licensing value above $120 billion, with upfront payments exceeding $10 billion. Potential values include contingent payments; these figures do not measure exposure to the five entries and should not be combined into a growth series.
DO CHANGES APPLY TO PENDING DEALS?
From publication of the announcement until the revised Catalogue takes effect, the Chinese technology exporter must register an in-scope export through MOFCOM’s technology trade system before the export occurs. The specified transactions include overseas transfers of technology ownership, authorization to use technology abroad, and changes resulting in an overseas party becoming the owner or actual controller of technology in China. Exports that have begun but remain incomplete are included.
Buyers should ask counterparties to assess remaining deliveries and relevant ownership or control changes, even for signed agreements. Registration alone does not bring the draft prohibitions into force or establish a new approval process. A signed agreement does not exempt outstanding exports.
November 15 is the consultation deadline, not an announced commencement date. The registration form seeks recipient details, technology and use descriptions, and transaction values; buyers may wish to review relevant proposed disclosures for accuracy and consistency with the agreement.
Classification should take account of the control descriptions and exclusions included in Annex 1 of Announcement No. 48. The announcement does not separately explain how every draft exclusion operates during the interim period. A platform license coupled with a change in actual control warrants particular attention; neither a blanket filing requirement for every biotechnology license nor a blanket exemption for every ownership-retaining arrangement is established.
PLATFORM OWNERSHIP AND PRODUCT RIGHTS RECEIVE DIFFERENT TREATMENT
Two proposed prohibited-export entries address proprietary cell and gene therapy (CGT) technology platforms (262704J) and small interfering RNA (siRNA) drug technology platforms (262705J).[2] A platform is an accumulated, reusable set of underlying common technologies capable of supporting multiple drugs. Process technology used to develop a single drug is excluded from that definition. The siRNA control language should not be read as covering every nucleic-acid modality merely because the entry’s broader heading refers to small nucleic-acid drugs.
For these two entries, the prohibition would apply only to outbound transfers of platform ownership. Licenses and outsourced research or manufacturing services that do not transfer ownership are expressly excluded. A separate exclusion covers processes necessary for a specific drug’s development, testing, production, quality control, marketing, and compliance in international cooperation or business development transactions. The licensing exclusion is not expressly limited to single-product or nonexclusive licenses.
Purchasing ownership of a qualifying platform would face the proposed prohibition. An ownership-retaining license is excluded from these platform entries, but its scope must support the buyer’s intended development, manufacturing, and commercialization activities. A product-specific process transfer should be assessed separately from an assignment of the reusable platform underlying it. Products manufactured using listed technologies are outside these technology controls; accompanying technology transfers require their own assessment.
NOVEL-TARGET TECHNOLOGY REQUIRES A SEPARATE ANALYSIS
Two proposed restricted-export entries (262705X and 262706X) cover proprietary technologies for discovering and validating wholly novel drug targets in cell and gene therapy and siRNA. The definition turns on whether the target has been publicly disclosed anywhere worldwide, including through patents, academic literature, public databases, industry materials, or conferences. It does not separately require the discovery method itself to be novel. A patent application that has not been published does not, by itself, demonstrate public disclosure.
The controlled subject matter is technology used to screen, discover, and confirm such targets and identify potential sites of action. A candidate’s association with an undisclosed target does not alone establish that the entire product license is restricted; the technology being transferred must be identified. Conversely, the platform entries’ exclusions cannot simply be carried across; the target entries contain no express requirement that the technology support multiple drugs and no equivalent general exclusion for single-product cooperation.
Exports through licensing, joint research using overseas resources, and specified public-health or humanitarian activities would receive automatic licensing or other facilitation under the proposal. These arrangements remain within the restricted-export framework. Their procedures, timing, and interaction with existing licensing requirements require clarification.
AN ACQUISITION MUST BE ASSESSED BEYOND THE IP ASSIGNMENT
Under Announcement No. 48, a share acquisition may trigger interim registration where an overseas buyer becomes the actual controller of technology in China, even if the Chinese target continues to hold legal title to the intellectual property (IP). The proposed platform prohibition, however, is expressly framed around ownership transfers. How it would apply to a share transaction without an IP assignment remains unresolved.
Maintaining IP title in a Chinese subsidiary therefore does not settle every issue, while a minority investment without a relevant ownership or control change should not automatically be treated as registrable on that basis.
The same questions arise when a multinational buyer acquires rights through an offshore “NewCo.” The analysis should follow the technology, licensed rights, contribution arrangements, and later acquisition options. An option requiring a later platform assignment could lose value if that assignment becomes prohibited under the final rules.
Where platform ownership remains with the counterparty, the buyer should test whether the license and support arrangements permit follow-on programs, manufacturing transfers, and use by affiliates or contract manufacturers. Improvements and step-in rights should be reviewed against the technology actually transferred. Buyers should consider whether the required technical package and assistance would remain accessible if the counterparty cannot perform.
PATHOGEN-RELATED PROGRAMS NEED SEPARATE SCREENING
Proposed prohibited-export entry 267302J covers specified pathogen genetic-modification and directed-passaging technologies meeting any of three listed characteristics. These include gain-of-function technology for known or potential pathogens and specified passaging systems or induction technologies. CGT programs using viral vectors should also be screened against this entry’s actual criteria; using a viral vector alone does not establish coverage.
The entry does not require a proprietary, multidrug platform. Neither the platform-license exclusions nor therapeutic purpose supplies a general exemption, and restricted-technology automatic licensing does not override this proposed prohibition.
WHAT SHOULD MULTINATIONAL BUYERS DO NOW?
Map the Required Technology and Deliveries
Ask the counterparty for an entry-by-entry classification supported by scientific input, relevant IP ownership records, and target-disclosure evidence. Match that assessment to the diligence materials, technology-transfer package, services, and post-closing updates the buyer actually needs. Assess sensitive technical disclosures before access is granted; a nondisclosure agreement does not replace required authorization.
Confirm the Process Before Fixing the Timetable
Identify who must register or apply, what evidence the buyer will receive, and which steps must precede disclosure, signing, or closing. Under ordinary restricted-technology procedures, a government-issued technology export license letter of intent is required before substantive negotiations and signing.
The technology export contract takes effect only when the final export license is issued.[3] The draft alone does not apply these procedures to previously unrestricted technology; the procedures’ interaction with proposed automatic licensing remains to be clarified.
Negotiate Rights That Support the Operating Plan
For bundled deals, separate product rights, platform-use rights, and target-discovery technology in the scope of grant and delivery schedules. Assess each component rather than relying on a single license-out label. Address sublicensing, manufacturing transfers, improvements, continuing assistance, and later acquisitions. Test whether any fallback preserves the capabilities needed for global development and supply.
Allocate Regulatory and Performance Risk
Distinguish required registration from discretionary approval when setting conditions. Consider representations on ownership and applicable filing compliance, supported by technical evidence rather than the license-out label alone. Address filing cooperation, delivery milestones, a suitable long-stop date, and remedies if essential rights or support cannot lawfully be provided. Consider allocating payment triggers to separately deliverable rights where platform ownership, manufacturing independence, or a later acquisition is central to the economics.
Check Parallel Requirements
A Catalogue exclusion does not remove existing technology-export contract registration requirements or independently applicable dual-use controls. Review other requirements separately if regulated data or human genetic resources form part of the transaction. Investment and other jurisdictions’ restrictions also remain separate.
For US buyers, biotechnology is not a standalone category under current 31 CFR Part 850. The Comprehensive Outbound Investment National Security Act already authorizes the US Department of the Treasury to add categories supporting specified military, intelligence, surveillance, or cyber capabilities, subject to congressional consultation and rulemaking. The Biotech Investment National Security Act bills H.R. 9102 and S. 5316 would address biotechnology and licensing prohibited technology from covered foreign persons; neither is law as of October 16. A China-side exclusion therefore does not settle the US analysis.
ISSUES TO ADDRESS DURING CONSULTATION
For multinational buyers, useful clarification would address control changes without IP assignments, the interim application of platform exclusions, the boundary of a target, automatic-licensing procedures, and continuing deliveries under existing agreements. Buyers may wish to submit transaction-specific examples by November 15, without disclosing unnecessary confidential information. The answers will affect the rights available, the feasibility of technology transfers, and allocation of execution risk.
